wire - news in brief


Category



Results 151 - 200 of 297.

Astronomy - Administration/Government
17.01.2018
Investigation launched
ETH Zurich's Executive Board has launched an investigation into allegations of research misconduct by a professor in the former Institute for Astronomy.
Medicine/Pharmacology - Life Sciences
17.01.2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Filing acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy EMA granted accelerate
Physics/Materials Science
17.01.2018
Sweat torso to become international
Sweat torso to become international
Empa's sweat torso now meets the ISO standard. How protective clothing affects the human body can be investigated in future with Empa's torso in a standardized way. If a firefighter enters a burning building in full gear, the heat of the fire must not harm him. Appropriate protective clothing protects the wearer from burns, but at the same time it must enable him/her to compensate for the high ambient temperatures by sweating.
Medicine/Pharmacology - Environment/Sustainable Development
16.01.2018
Novartis new data reinforces superiority of Cosentyx versus Stelara * in achieving skin clearance for psoriasis patients
Results from CLARITY study show Cosentyx (secukinumab) was significantly more effective than Stelara * (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks Data support findings from the CLEAR study, which found Cosentyx was superior to Stelara * in achieving sustained skin clearance (PASI 90) at 52 weeks Cosentyx is the first and only fully human interleukin-17A (IL-17A) inhibitor that showed sustained skin cleara
Architecture - Computer Science/Telecom
15.01.2018
Insulating with microscopic bubbles
Insulating with microscopic bubbles
Better thermal insulation means lower heating costs - but this should not be at the expense of exciting architecture.
Innovation/Technology - Event
11.01.2018
Efficient energy from biowaste - Watt d'Or for PSI and Energie 360°
Efficient energy from biowaste - Watt d’Or for PSI and Energie 360°
Efficiently producing energy from biowaste: A technology developed at PSI and tested in collaboration with the Zurich-based energy provider Energie 360 makes it possible.
Medicine/Pharmacology - Business/Economics
11.01.2018
Sport Sciences - Medicine/Pharmacology
11.01.2018
Life Sciences - Computer Science/Telecom
11.01.2018
Blue Brain Nexus: an open-source tool for data-driven science
Knowledge sharing is an important driving force behind scientific progress. In an open-science approach, EPFL's Blue Brain Project has created and open sourced Blue Brain Nexus that allows the building of data integration platforms.
Medicine/Pharmacology - Life Sciences
09.01.2018
Novartis advances head-to-head superiority trials of Cosentyx versus Humira * and proposed biosimilar adalimumab**
SURPASS is the firsthead-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis(AS) EXCEED is the firsthead-to-head superiority trial versus Humira * inpsoria
Careers/Employment - Computer Science/Telecom
05.01.2018
Algorithm increases employment opportunities for refugees
A data-driven approach could help increase employment levels for asylum seekers in Switzerland from 15 to 26 percent.
Medicine/Pharmacology - Physics/Materials Science
04.01.2018
Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas
Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas New technology allows better testing and monitoring of HIV patients living in rem
Administration/Government - Careers/Employment
04.01.2018
Medicine/Pharmacology
04.01.2018
Novartis drug Promacta receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Data supporting designation showed over half of treatment-nave SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of
Medicine/Pharmacology - Life Sciences
03.01.2018
Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in preor perimenopausal women who received no prior endocrine therapy for advanced disease Treatment benefit with K
Computer Science/Telecom - Medicine/Pharmacology
28.12.2017
Looking back at 2017 (2/2)
Looking back at 2017 (2/2)
A dazzling victory at the Solar Decathlon, artificial intelligence generating melodies, virtual reality to reduce phantom pain, a robot-fish spy, 12 million francs for a Center of Artificial Muscles...Some of the EPFL's research and milestones that marked the year 2017.
Life Sciences - Medicine/Pharmacology
27.12.2017
Callous and Unemotional Traits Show in Brain Structure of Boys Only
Callous and Unemotional Traits Show in Brain Structure of Boys Only
Callous-unemotional traits are linked to differences in brain structure in boys, but not girls. This reports a European research team led by the University of Basel and University of Basel Psychiatric Hospital in a study on brain development in 189 adolescents.
Medicine/Pharmacology - Administration/Government
22.12.2017
Novartis’ combination therapy Tafinlar + Mekinist granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Novartis' combination therapy Tafinlar + Mekinist granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma Priority Review designation based on Phase I
Medicine/Pharmacology - Chemistry
22.12.2017
Novartis drug Tasigna is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
Inclusion of Treatment-free Remission (TFR) data provides additional and novel option in management of Ph+ CML-CP Deep and sustained molecular response included as key eligibility criteria for atte
Physics/Materials Science - Environment/Sustainable Development
21.12.2017
Clear-cut ideas
Clear-cut ideas
Tanja Zimmermann joined Empa's Board of Directors in September. She runs the new Functional Materials department - another step up in a successful career that began in Empa's Wood lab. Thanks to her inquisitiveness, creativity and an eye for the impossible, Zimmermann helped lift a previously little-known research field onto the international stage "Creativity is a basic requirement in research." Tanja Zimmermann is speaking from experience.
Medicine/Pharmacology - Life Sciences
21.12.2017
European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
European Commission approves Roche's Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer Alecensa provides a new treatment option for people with newly diagnosed ALK-positive NSC
Civil Engineering
21.12.2017
A bench out of glass that's as resistant as steel
A bench out of glass that's as resistant as steel
A PhD student in civil engineering at EPFL and a recent architecture graduate joined forces to make a bench out of exceptionally resistant glass.
Innovation/Technology - Business/Economics
19.12.2017
Teams up with partner organizations to build "digital trust"
EPFL President Martin Vetterli has today unveiled plans to create the EPFL Center for Digital Trust.
Environment/Sustainable Development
18.12.2017
Physics/Materials Science - Environment/Sustainable Development
18.12.2017
Medicine/Pharmacology - Business/Economics
15.12.2017
Medicine/Pharmacology - Business/Economics
14.12.2017
Physics/Materials Science
13.12.2017
Reading ancient sealed documents
Scientists see inside a sealed testament from the State Archives of Venice using EPFL technology - without breaking the wax seal - and reveal the last wishes of a Venetian lady from the year 1351. EPFL physicists reveal the last wishes of a Venetian woman from the year 1351 contained in a wax-sealed document, without breaking the seal.
Medicine/Pharmacology - Life Sciences
12.12.2017
Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated c
Medicine/Pharmacology - Life Sciences
12.12.2017
Medicine/Pharmacology - Life Sciences
11.12.2017
Using 3D cell cultures to fight anti-cancer therapy resistance
Using 3D cell cultures to fight anti-cancer therapy resistance
An international research team headed by the University of Bern and the Netherlands Cancer Institute has developed 3D cell cultures in which genes can be specifically modified. They allow the study of genes that may cause therapy resistance in breast cancer. This knowledge may further improve the use of targeted anti-cancer drugs.
Social Sciences - Innovation/Technology
11.12.2017
Social Sciences - Innovation/Technology
11.12.2017
Physics/Materials Science - Environment/Sustainable Development
11.12.2017
Life Sciences - Environment/Sustainable Development
11.12.2017
Law/Forensics - Administration/Government
11.12.2017
Ontario Should Revise Discriminatory Policy Against Refugee Drivers
Allow experienced drivers from war-torn countries to skip driving-test waiting period similar to other newcomers in Ontario Toronto, ON -Ontario's Ministry of Transportation should revise its policy
Medicine/Pharmacology - Life Sciences
10.12.2017
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer At six
Medicine/Pharmacology - Innovation/Technology
08.12.2017
Life Sciences - Medicine/Pharmacology
08.12.2017
Acrobatic Duo in the Cells
Acrobatic Duo in the Cells
Just like an acrobatic duo, some proteins lend each other stability. Researchers at the Biozentrum of the University of Basel have discovered that the protein ‘Trigger factor' recognizes a partner by instable, flexible domains, to then together form a stable protein duo. The study has been published in the current issue of ‘Nature Communications'.
Astronomy - Earth Sciences
07.12.2017
Medicine/Pharmacology - Computer Science/Telecom
07.12.2017
Using artificial intelligence to advance personalized medicine
Opened less than a year ago, the Swiss Data Science Center - a joint initiative between EPFL and ETH Zurich - has already launched eight research projects in fields ranging from personalized medicine and environmental protection to open science. Each project brings together experts from several disciplines to join forces in tackling some of society's biggest challenges.
Medicine/Pharmacology - Business/Economics
07.12.2017
Medicine/Pharmacology - Life Sciences
07.12.2017
Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer
Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer First Phase III combination trial of a cancer immunotherapy to show improvement in progression-free survival as an initial treatment in advanced non-squamous non-small-cell lung cancer (NSCLC) Roche today announced results from the positi
Medicine/Pharmacology
06.12.2017
Novartis Kisqali is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to
Novartis Kisqali is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to..